Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Diurnal patterns of soluble amyloid precursor protein metabolites
in the human central nervous system
Justyna A. Dobrowolska
Washington University School of Medicine in St. Louis

Tom Kasten
Washington University School of Medicine in St. Louis

Yafei Huang
Washington University School of Medicine in St. Louis

Tammie L. S. Benzinger
Washington University School of Medicine in St. Louis

Wendy Sigurdson
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Dobrowolska, Justyna A.; Kasten, Tom; Huang, Yafei; Benzinger, Tammie L. S.; Sigurdson, Wendy; Ovod,
Vitaliy; Morris, John C.; and Bateman, Randall J., ,"Diurnal patterns of soluble amyloid precursor protein
metabolites in the human central nervous system." PLoS One. 9,3. e89998. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2890

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Justyna A. Dobrowolska, Tom Kasten, Yafei Huang, Tammie L. S. Benzinger, Wendy Sigurdson, Vitaliy
Ovod, John C. Morris, and Randall J. Bateman

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/2890

Diurnal Patterns of Soluble Amyloid Precursor Protein
Metabolites in the Human Central Nervous System
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Vitaliy Ovod1, John C. Morris1,2,4, Randall J. Bateman1,4,5*
1 Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Pathology and Immunology,
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Missouri, United States of America, 4 Charles F. and Joanne Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri,
United States of America, 5 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract
The amyloid-b (Ab) protein is diurnally regulated in both the cerebrospinal fluid and blood in healthy adults; circadian
amplitudes decrease with aging and the presence of cerebral Ab deposits. The cause of the Ab diurnal pattern is poorly
understood. One hypothesis is that the Amyloid Precursor Protein (APP) is diurnally regulated, leading to APP product
diurnal patterns. APP in the central nervous system is processed either via the b-pathway (amyloidogenic), generating
soluble APP-b (sAPPb) and Ab, or the a-pathway (non-amyloidogenic), releasing soluble APP-a (sAPPa). To elucidate the
potential contributions of APP to the Ab diurnal pattern and the balance of the a- and b- pathways in APP processing, we
measured APP proteolytic products over 36 hours in human cerebrospinal fluid from cognitively normal and Alzheimer’s
disease participants. We found diurnal patterns in sAPPa, sAPPb, Ab40, and Ab42, which diminish with increased age, that
support the hypothesis that APP is diurnally regulated in the human central nervous system and thus results in Ab diurnal
patterns. We also found that the four APP metabolites were positively correlated in all participants without cerebral Ab
deposits. This positive correlation suggests that the a- and b- APP pathways are non-competitive under normal physiologic
conditions where APP availability may be the limiting factor that determines sAPPa and sAPPb production. However, in
participants with cerebral Ab deposits, there was no correlation of Ab to sAPP metabolites, suggesting that normal
physiologic regulation of cerebrospinal fluid Ab is impaired in the presence of amyloidosis. Lastly, we found that the ratio of
sAPPb to sAPPa was significantly higher in participants with cerebral Ab deposits versus those without deposits. Therefore,
the sAPPb to sAPPa ratio may be a useful biomarker for cerebral amyloidosis.
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were in good general health. These participants were divided into
three groups by age and brain amyloid status: 1) an Amyloid+
group of participants greater than 60 years of age and with
probable amyloid plaques in the brain. Amyloid plaque status was
determined by positron emission tomography using Pittsburgh
compound B (PET PiB) or determined by an Ab42 CSF mean
concentration less than 350 pg/mL; 2) an Amyloid2 age-matched
group with no probable amyloid plaques in the brain as measured
by PET PiB or determined by an Ab42 CSF mean concentration
greater than 350 pg/mL; 3) a Young Normal Control (YNC)
group (18–50 years of age) that are likely PET PiB- [15]. PiB binds
to fibrillar amyloid plaques in the brain [16]. A mean cortical
binding potential (MCBP) was calculated for each participant to
determine PET PiB (Amyloid) ‘‘+’’ or ‘‘2’’ status [15]. To measure
the MCBP, binding potentials of PiB were averaged from specific
brain regions: prefrontal cortex, precuneus, lateral temporal
cortex, and gyrus rectus. MCBP scores of 0.18 or greater were
designated as amyloid plaque positive (Amyloid+), while those less
than 0.18 were designated as amyloid plaque negative (Amyloid2)
[15]. Some participants did not have reported MCBP values, and,
in those cases, a surrogate marker of amyloid deposition was used
to assign the participant group. This surrogate marker was a low
CSF Ab42 concentration which has been shown to be inversely
correlated with PET PiB measurements [17]. A CSF Ab42
concentration was considered low (and the participant classified
as Amyloid+) if it was detected as less than 350 pg/mL from an
Ab42 ELISA that used 21F12 (anti-Ab42) as the capture antibody
and biotinylated 3D6 antibody (directed against Ab1–5) as the
detection antibody.

Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting an estimated 30 million people worldwide
[1]. Although the pathophysiology of this disease is incompletely
understood, the study of brain and cerebrospinal fluid (CSF)
proteins, such as amyloid-b (Ab) and tau, have provided insight
into AD molecular pathophysiology [2–6]. The study of Ab
production, transport, and clearance is important for insight into
normal brain protein handling and also for the pathophysiology of
AD.
The first studies of Ab concentrations over time indicated that
CSF concentrations were sinusoidal over 24 hours in younger
healthy participants [7] and suggested a possible circadian pattern.
Subsequent studies in humans and animal models [8] demonstrated Ab concentrations in the brain could be regulated by
sleep/wake cycles and orexin. We reported that Ab exhibits a
diurnal pattern in both CSF [9] and blood [10] in healthy adults.
The diurnal patterns, as determined by circadian amplitude,
decreased with aging and amyloidosis. The immediate mechanism
for diurnal regulation of Ab has not been previously described,
and possible causes for the Ab diurnal pattern include, but are not
limited to, diurnal regulation of Amyloid Precursor Protein (APP)
transcription, translation, or transport, or diurnal regulation
affecting the two secretases (b-secretase or c-secretase) that cleave
APP to produce Ab. In this study, we evaluated the temporal
relationship of Ab with other proteolytic products of APP to
inform about the cause of Ab diurnal patterns in the CNS of
healthy young and elderly humans, as well as those with amyloid
pathology.
Amyloid precursor protein is a single-pass transmembrane
protein processed through at least two pathways in the CNS: the
b- (amyloidogenic) pathway and the a- (non-amyloidogenic)
pathway [11]. This protein is cleaved in the amyloidogenic
pathway by b-secretase releasing a soluble extracellular fragment
called soluble APPb (sAPPb) [12–14]. The APP endodomain, Cterminal fragment 99 (CTF99), which remains in the transmembrane, is subsequently cleaved by c-secretase, resulting in the
generation of Ab and the APP Intra-Cellular Domain (AICD).
The non-amyloidogenic processing of APP occurs when asecretase cleaves APP, producing soluble APPa (sAPPa). The
endodomain of APP (CTF83) may then be cleaved by c-secretase,
resulting in the release of a fragment, p3. The formation of Ab is
precluded by a-secretase cleavage.
To further elucidate the potential contributions of APP to the
Ab diurnal pattern and the balance of the a- and b- pathways in
APP processing, we measured APP proteolytic products sAPPb,
sAPPa, Ab40, and Ab42 over 36 hours in CSF from cognitively
normal young and elderly participants, as well as in CSF from
participants with AD.

Demographics of study participants
A total of 49 participants (both men and women) were assessed
in at least one part of this study. Specific sample size in each group
varied depending on the experiment, and sample size for each
group when diurnal patterns were observed is listed in the cosinor
analyses section of the Methods. For the part of this study where
APP metabolites were measured in a single CSF time point, there
were 15 participants in the YNC group, 15 in Amyloid2, and 18
in Amyloid+.
The mean (SD) age for each participant group when all 49
participants were taken into account: YNC = 37.11 (68.71) years;
Amyloid2 = 69.6 (64.5) years; and Amyloid+: 76.3 (67.5) years.
Clinical Dementia Rating (CDR) at study onset was available for
all participants. Of the Amyloid2 participants, 33.3% had a CDR
score greater than zero (exhibited cognitive deficits). Of the
Amyloid+ participants, 29.4% had a CDR score equal to zero. All
YNC subjects were free from any cognitive deficits.

Sample collection and storage
Sample collection and handling were done as previously
described [18]. Briefly, for all participants an intrathecal lumbar
catheter was placed between the L3 and L4 interspace or the L4
and L5 interspace between 7:30 A.M. and 9:00 A.M. Collection of
CSF began between 8:00 A.M. and 9:30 A.M. Every hour for
36 hours, 6 mL of CSF and 12 mL of plasma were withdrawn.
Aliquots of CSF (1 mL) were immediately frozen at 280uC in
Axygen maximum-recovery polypropylene tubes.

Materials and Methods
Ethics statement
All human studies were approved by the Washington University
Human Studies Committee and the General Clinical Research
Center (GCRC) Advisory Committee. Written, informed consent
was obtained from all participants prior to their enrollment in this
study.

Sample and standard handling
Aliquots (1 mL) from even hours with two freeze-thaw cycles
were measured by sAPPa and sAPPb ELISA. The effect of two
freeze-thaw cycles was determined to not significantly change
sAPPa and sAPPb concentrations. Before plating, CSF samples
were diluted in phosphate buffered saline-0.05% Tween20 (PBS-

Study design
Participants were recruited from the general public or through
Washington University’s Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC). All participants
PLOS ONE | www.plosone.org
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at 650 nm using a Biotek Synergy 2 plate reader after 5–
30 minutes.
We tested the specificity of the sAPPb assay by running a
titration curve of the sAPPb and sAPPa protein standards on the
same ELISA. The results demonstrated that this assay was specific
for sAPPb and that cross-reactivity with sAPPa was negligible.
The OD value for the sAPPb standard of 8.5 ng/mL was
approximately the same as that for the sAPPa standard of 300 ng/
mL (Figure S2). This indicated that this ELISA was approximately
35-fold more selective for sAPPb than for sAPPa. The diluted CSF
OD values fell within a linear range of the sAPPb standard curve
and well above the highest sAPPa standard’s (300 ng/mL) OD
value. Given that in biological samples sAPPa and sAPPb were
nearly equal in molar concentrations, this minimal cross-reactivity
of sAPPa in the sAPPb ELISA was negligible. Thus, we concluded
that any fluctuations we observed in sAPPb levels using this ELISA
were attributed solely to sAPPb, and not to sAPPa.

T) 75- to 150-fold for sAPPa, and 10- to 25-fold for sAPPb.
Recombinant standards from E.coli were used for both sAPPa
(Sigma-Aldrich; St. Louis, MO) and sAPPb (Sigma-Aldrich; St.
Louis, MO). The concentration of the standards ranged from 1.6–
75 ng/mL for sAPPa and 2.7–125 ng/mL for sAPPb. Single
freeze-thaw CSF aliquots from both odd and even hours were
thawed on ice for the Ab40 and Ab42 ELISAs. They were diluted
in a final buffer consisting of 2 mg/mL BSA (bovine serum
albumin (Sigma-Aldrich; St. Louis, MO))-PBS-T, 3 M Tris, 10%
Azide, 16 protease inhibitor cocktail. Each CSF and standard
sample was assessed in triplicate.

sAPPa ELISA protocol
For the sAPPa ELISAs, 96-well Nunc MaxiSorp flat bottom
ELISA plates (eBiosciences, Inc.; San Diego, CA) were coated with
100 mL per well of 5 mg/mL of 8E5 (a monoclonal antibody raised
to a bacterially expressed fusion protein corresponding to human
APP444–592 of the APP770 transcript [19], courtesy of Eli Lilly).
Plates were incubated for 24 hours on a shaker at 4uC, and then
blocked with 3% dry milk in PBS-T for 1 hour 20 minutes at
37uC. To avoid plate position effects, samples were randomly
assigned to a well on the plate. Secondary (detection) antibody
(50 mL of 1:10,000 6E10 [20], a monoclonal antibody reactive to
Ab1–16, otherwise known as APP672–687 (in the APP770 transcript),
and having the epitope at Ab3–8, or APP674–679) (Signet Covance;
Dedham, MA) was added to each well. Samples and secondary
antibody were incubated on a shaker at 4uC for 24 hours. Plates
were washed 5 times with PBS-T and then Streptavidin PolyHRP20 (Fitzgerald Industries International; Acton, MA), diluted
at 1:15,000 in 1% BSA-PBS-T, was added to each well at 100 mL/
well. Plates were incubated in the dark for 1 hour at 37uC on a
shaker. Plates were then washed 5 times with PBS-T and 5 times
with PBS. The plates were developed as described for the sAPPb
ELISA below.
To test the specificity of the sAPPa assay, we ran a titration
curve of sAPPa and sAPPb protein standards on the same ELISA.
The results demonstrated that this assay was specific for sAPPa
and there was no detectable cross-reactivity with sAPPb, as even
the highest sAPPb standard (300 ng/mL) did not produce an OD
value above zero (Figure S1). The diluted CSF OD values fell
within a linear range of the sAPPa standard curve

Ab40 and Ab42 ELISA protocols
Corning 96-well half area clear flat bottom polystyrene high
bind ELISA plates (Corning Life Sciences, Tewksbury, MA) were
coated with 1.25 mg/mL HJ7.4 (Ab37–42) or 2.5 mg/mL HJ2
(Ab33–40) in PBS plus 20% glycerol (PBS-G), then incubated
1 hour at 25uC followed by overnight incubation at 4uC. The next
day the plates were blocked with 2% BSA-PBS-T for 90 minutes
at 4uC. Samples were randomly assigned a well on the plate.
Diluted CSF samples and standards were pipetted at a volume of
50 mL per well onto freshly washed plates. The samples were
loaded in triplicate and incubated overnight at 4uC. After
incubation and washing, the plates were incubated for 90 minutes
at 25uC with 0.2 mg/mL HJ5.1-Biotin (Ab13–28) in 1% BSA-PBST-G. Plates were then washed three times with 190 mL PBS-T,
followed by incubation in Streptavidin Poly-HRP40 (Fitzgerald
Industries International; Acton, MA), diluted at 1:12,000 in 1%
BSA-PBS-T-G, for 90 minutes at 25uC. Plates were subsequently
washed three times with 190 mL PBS-T. They were then
incubated with 50 mL/well of Slow ELISA TMB (pre-warmed
to 25uC) for 5–30 minutes. Optical density (OD) was read at
650 nm using a Biotek Synergy 2 plate reader.

CSF protein level quantification
Soluble APPa, sAPPb, Ab40, and Ab42 concentration levels
were quantified using the Biotek Gen5 software (version #1.08.4)
based on the non-linear five parametric standard curves generated
from the recombinant sAPPa, sAPPb, Ab40, and Ab42 standards.
The OD values of the CSF samples fell within the linear range of
the standard curve and were converted to concentration levels.
The product of the concentration and the dilution factor was
calculated in order to determine the final CSF concentration of
each protein.
Total protein levels of each sample were measured by BCA
assay (Thermo Fisher Scientific, Inc.; Rockford, IL) as previously
reported [9]. The intra-sample coefficient of variation mean was
2% for duplicates.

sAPPb ELISA protocol
For the sAPPb ELISA, 96-well Nunc MaxiSorp flat bottom
ELISA plates (eBiosciences, Inc.; San Diego, CA) were coated with
100 mL per well of 10 mg/mL of the monoclonal antibody, 8E5.
Plates were incubated for 24 hours on a shaker at 4uC and
subsequently blocked with 3% dry milk in PBS-T for 1 hour
20 minutes at 37uC. Samples were randomly assigned a plate well
position and incubated for 24 hours on a shaker at 4uC. They
were then washed 5 times with PBS-T. An antibody against the
neo-epitope of sAPPb (APP670/671 of the APP770 transcript)
(courtesy of Eli Lilly) was used as the secondary (detection)
antibody at a volume of 50 mL and a concentration of 0.5 mg/mL,
diluted in PBS-T pre-warmed to 37uC. The sAPPb detection
antibody was added to each well and incubated at 37uC for
90 minutes. Plates were washed 10 times with PBS-T, and 100 mL
Streptavidin Poly-HRP40 (Fitzgerald Industries International;
Acton, MA), diluted at 1:20,000 in 1% BSA-PBS-T, was added
to each well. Plates were incubated in the dark for 1 hour at 25uC
on a shaker and washed 5 times with PBS-T and 5 times with PBS.
For the sAPPa and sAPPb ELISAs, 100 mL/well of ELISA TMB
Super Slow (Sigma-Aldrich; St. Louis, MO), pre-warmed to 25uC,
was then added to each well. Optical density (OD) was measured
PLOS ONE | www.plosone.org

Group-averaged cosinor analyses
Serial sAPPa and sAPPb concentrations were binned in two
hour increments as samples were from every other hour. Serial
Ab40 and Ab42 concentrations were left unbinned because hourly
concentrations were measured. For each APP metabolite, each
participant’s hourly metabolite’s concentration was normalized to
that metabolite’s mean concentration over 36 hours. The
normalized value was calculated as a percentage of each
participant’s mean (1006value/mean). Hourly (Ab40 and Ab42)
3
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and bi-hourly (sAPPa and sAPPb) concentrations of each
metabolite were averaged among all participants in each
participant group to produce normalized mean 36 hour concentrations. Next, the linear concentration rise over time that was
observed in each metabolite was subtracted out of the mean
concentrations and a single cosinor fit was applied for each
metabolite as described previously [9]. Briefly, a cosine transformation was applied to the time variable using 24 hours as the
default circadian cycle, and Graphpad Prism version 5.01 for
Windows (GraphPad Software; San Diego, CA) was used to
estimate the parameters of the circadian rhythms for each
metabolite. The amplitude (distance between the peak to the
midline of the cosine wave) was determined for each participant
group. For all cosinor analyses, the YNC group consisted of 13
participants. The Amyloid2 group included 19 participants for
sAPPa and sAPPb cosinor analyses, and 15 participants for Ab40
and Ab42 cosinor analyses. The Amyloid+ group had 17
participants for sAPPa and sAPPb cosinor analyses, and 14
participants for Ab40 and Ab42 cosinor analyses.

Group-averaged sAPPa and sAPPb circadian amplitudes
lower with older age
When a 24 hour cosine curve was fit to the three groupaveraged sAPPa hourly concentrations, the YNC group exhibited
an amplitude that significantly deviated from zero (2.9%) and was
significantly greater than the Amyloid2 (0.9%) and Amyloid+
(2%) groups, which both did not deviate significantly from zero
(Figure 1A–C). A similar trend was observed when a cosine curve
was fit to the three group-averaged sAPPb hourly concentrations
(Figure 1D–F). Amplitude of sAPPb for the YNC group was 4.4%,
Amyloid2 was 1.2%, and Amyloid+ was 2%. Only the sAPPb
amplitude of the YNC group significantly deviated from zero.
Amplitude of Ab40 for the YNC group was 0.9%, Amyloid2 was
3.2%, and Amyloid+ was 2.6% (Figure 1G–I). Only the Ab40
amplitude of the Amyloid2 group significantly deviated from
zero. Amplitude of Ab42 for the YNC group was 2.9%, Amyloid2
was 3.8%, and Amyloid+ was 0.4% (Figure 1J–L). Only the Ab42
amplitude of the YNC group significantly deviated from zero.

Individual sAPPa and sAPPb amplitude-to-mesor values
decrease with age; Ab40 and Ab42 amplitude-to-mesor
values unchanged

Individual cosinor analyses
For each participant, sAPPa, sAPPb, Ab40, and Ab42 levels over
36 hours were analyzed using a single cosinor analysis as described
above. Mesor (midline of the metabolite oscillation), amplitude
(distance between the peak and mesor), amplitude-to-mesor ratio,
and acrophase (time at which the peak occurs) were calculated for
each metabolite for each participant. Then, participant group
means for each of the metabolites’ cosinor parameters were
determined. Group sample size for these analyses was the same as
for the group-averaged cosinor analyses.

To control for differences in average values of amplitude and
mesor among participants, the amplitude-to-mesor ratios were
calculated for each group. In the YNC group, sAPPa amplitudeto-mesor ratio was, on average, 10.93% (min.: 2.3%, max.:
18.2%). Both the Amyloid2 (6.7%; Min: 1.2%, max.: 14.0%;
*p = 0.01) and Amyloid+ (6.0%; min.: 1.5%, max.: 20.1%;
*p = 0.01) groups had significantly lower sAPPa amplitude-tomesor ratios than YNC. There was no significant difference
between the Amyloid2 and Amyloid+ groups (p = 0.6) (Table 1;
Figure 2B).
Similar trends were observed among groups when sAPPb
amplitude-to-mesor ratio was measured. In YNC, the mean
sAPPb amplitude-to-mesor ratio was 14.38% (min.: 3.8%, max.:
21.2%). The Amyloid2 (8.15%; min.: 1.7%, max.: 19.9%;
**p = 0.003) and Amyloid+ (9.16%; min.: 1.9%, max.: 23.3%;
*p = 0.02) groups had significantly lower sAPPb amplitude-tomesor ratios than YNC. However, Amyloid2 and Amyloid+
groups did not significantly differ from one another (p = 0.6)
(Table 2; Figure 2D).
On the contrary, the Ab40 amplitude-to-mesor ratio was not
statistically different among all three groups. In YNC, the mean
Ab40 amplitude-to-mesor ratio was 8.46% (min.: 2.2%, max.:
18.5%). The Amyloid2 group had a mean Ab40 amplitude-tomesor ratio of 9.13% (min.: 2.7%, max.: 16%) and the Amyloid+
group had a mean Ab40 amplitude-to-mesor ratio of 9.09% (min.:
2.8%, max.: 24.4%). None of these groups’ Ab40 amplitude-tomesor ratios were significantly different from one another (YNC
vs. Amyloid2: p = 0.7; YNC vs. Amyloid+: p = 0.8; Amyloid2 vs.
Amyloid+: p = 0.99) (Table 3; Figure 2F).
When Ab42 amplitude-to-mesor ratio was measured, similar
trends to the Ab40 amplitude-to-mesor ratios were observed. In
YNC, the mean Ab42 amplitude-to-mesor ratio was 9.43% (min.:
1.9%, max.: 18.5%). The Amyloid2 group had a mean Ab42
amplitude-to-mesor ratio of 8.04% (min.: 3.6%, max.: 23.5%) and
the Amyloid+ group had a mean Ab42 amplitude-to-mesor ratio of
7.99% (min.: 2.2%, max.: 22%). None of these groups’ Ab42
amplitude-to-mesor ratios were significantly different from one
another (YNC vs. Amyloid2: p = 0.5; YNC vs. Amyloid+: p = 0.5;
Amyloid2 vs. Amyloid+: p = 0.98) (Table 4; Figure 2H).

Statistical analyses
Analyses were performed using Microsoft Office Excel 2007 and
GraphPad Prism version 5 for Windows (GraphPad Software, San
Diego, California, USA). Student’s t-tests and ANOVAs were used
to determine whether there were differences in cosinor parameters
between groups. 95% confidence intervals were reported. Correlations between APP metabolites were measured by calculating the
correlation coefficient (Pearson r values reported). Soluble APPa,
sAPPb, and sAPPb/a ratio were compared among groups using a
student’s t-test and ANOVA. 95% confidence intervals were
reported.

Results
Circadian patterns of APP metabolites
In order to determine APP processing over time within the same
participant, temporal CSF samples from a particular participant
were randomly assigned a well position on four sandwich ELISAs:
specific for sAPPa, sAPPb, Ab40, or Ab42. This allowed for
analysis of APP metabolite concentrations in the CSF over time.
To compare age and amyloid deposition effects on hourly
dynamics of APP metabolites, the Young Normal Control
(YNC) group was compared to the Amyloid2 and Amyloid+
groups.

sAPPa and sAPPb exhibit circadian patterns
Cerebrospinal fluid sAPPa and sAPPb hourly concentrations
had significant fits to a 24 hour cosinor pattern in the YNC group.
The average amplitude of the diurnal pattern for sAPPa was
2.9%61.3% (SEM) (Figure 1A). For sAPPb, the average
amplitude was 4.4%61.6% (SEM) (Figure 1D).

PLOS ONE | www.plosone.org
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Figure 1. Group-averaged diurnal rhythms of four APP metabolites are present. Cosinor fits were applied to each participant group’s
percentage of the mean for 36 hours of a particular APP metabolite’s concentration. This was done after adjusting for each participant’s individual
baseline and subtracting out the group’s linear increase in concentration over time. Results from all three participant groups are reported for sAPPa
(A–C), sAPPb (D–F), Ab40 (G–I), and Ab42 (J–L).
doi:10.1371/journal.pone.0089998.g001

The Amyloid2 group had a mean sAPPb amplitude that was 40%
lower (32.78 ng/mL; min.: 5.4 ng/mL, max.: 111.1 ng/mL) than
YNC (*p = 0.05), whereas the Amyloid+ group had a mean sAPPb
amplitude that was 42% lower (31.57 ng/mL; min.: 2.4 ng/mL,
max.: 93.7 ng/mL) than YNC (*p = 0.02). There was no
significant difference in sAPPb amplitude between the Amyloid2
and Amyloid+ groups (p = 0.9) (Table 2; Figure 2C).
For the YNC group, the mean Ab40 amplitude was 698.8 pg/
mL (min.: 287.3 pg/mL, max.: 1834 pg/mL). There was a trend
for decreased mean Ab40 amplitude with age. The Amyloid2
group had a mean Ab40 amplitude of 526.3 pg/mL (min.:
148.1 pg/mL, max.: 1138 pg/mL) and the Amyloid+ group had
a mean Ab40 amplitude of 505.5 pg/mL (min.: 90.55 pg/mL,
max.: 1381 pg/mL). This trend did not reach statistical significance (YNC vs. Amyloid2: p = 0.29; YNC vs. Amyloid+: p = 0.27;
Amyloid2 vs. Amyloid+: p = 0.89) (Table 3; Figure 2E).
In contrast, the mean Ab42 amplitudes were significantly
different among all groups. In the YNC the mean Ab42 amplitude

Individual Ab42 amplitude values decrease with age and
amyloidosis, as sAPPb amplitude decreases with age;
sAPPa and Ab40 amplitudes are not significantly different
among groups
On average, for YNC the sAPPa amplitude was 75.74 ng/mL
(min.: 7.7 ng/mL, max.: 139.1 ng/mL), in Amyloid2 it was
59.24 ng/mL (min.: 15.1 ng/mL, max.: 149.7 ng/mL), and in
Amyloid+ it was 51.1 ng/mL (min.: 15.3 ng/mL, max.: 155.8 ng/
mL). Although a trend toward a decrease of sAPPa amplitude with
increase in age was observed, the groups were not significantly
different by their sAPPa mean amplitudes (YNC vs. Amyloid2:
p = 0.2; YNC vs. Amyloid+: p = 0.1; Amyloid2 vs. Amyloid+:
p = 0.5) (Table 1; Figure 2A).
However, with respect to sAPPb mean amplitudes there was a
significant difference between YNC and either the Amyloid2 or
the Amyloid+ group. The sAPPb mean amplitude in the YNC
group was 54.61 ng/mL (min.: 21.8 ng/mL, max.: 92.2 ng/mL).
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Figure 2. Circadian rhythm parameters of four APP metabolites in YNC, Amyloid2, and Amyloid+ groups. A) Group-averaged sAPPa
amplitudes were not significantly different among groups. B) The sAPPa amplitude-to-mesor ratio was highest in YNC and significantly lower in
Amyloid2 (*p = 0.01) and Amyloid+ (*p = 0.01). There was no significant difference between the Amyloid2 and Amyloid+ groups (p = 0.6). C) Groupaveraged sAPPb amplitudes were significantly higher in YNC than in Amyloid2 (*p = 0.05) and Amyloid+ (*p = 0.02). D) The sAPPb amplitude-tomesor ratio was highest in YNC and significantly lower in Amyloid2 (**p = 0.003) and Amyloid+ (*p = 0.02). There was no significant difference
between the Amyloid2 and Amyloid+ groups (p = 0.6). E) Group-averaged Ab40 amplitude values were not significantly different among any of the
participant groups. F) Amplitude-to-Mesor ratio for Ab40 was also not significantly different among groups. G) Group-averaged Ab42 amplitudes were
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significantly highest in YNC when compared to Amyloid2 (*p = 0.04) and Amyloid+ (***p,0.0001). The Amyloid2 group also had a significantly
higher Ab42 amplitude than the Amyloid+ group (***p = 0.0008). H) The Ab42 amplitude-to-mesor ratios did not differ significantly among groups.
doi:10.1371/journal.pone.0089998.g002

YNC group (***p,0.0001) and a 60% lower mean Ab42 mesor
than the Amyloid2 group (***p,0.0001) (Table 4).

was 64.26 pg/mL (min.: 10.6 pg/mL, max.: 130.1 pg/mL). The
Amyloid2 group had a mean Ab42 amplitude that was 39% lower
(39.49 pg/mL; min.: 14.4 pg/mL, max.: 99 pg/mL) than the
YNC group (*p = 0.04). The Amyloid+ group had a mean Ab42
amplitude that was 77% lower (14.5 pg/mL; min.: 3.7 pg/mL,
max.: 41 pg/mL) than the YNC group (***p,0.0001) and 63%
lower than the Amyloid2 group (***p = 0.0008) (Table 4;
Figure 2G).

Individual acrophases are not significantly different with
age or amyloidosis
There is much inter-subject variability within groups for each
metabolite’s acrophase. Thus, any differences in time at peak/
trough among participant groups are not significantly different.
Data are provided in Tables 1–4. In the case of all four
metabolites, differences among average acrophase of participant
groups never reached statistical significance (p.0.05). Differences
among metabolites’ group-averaged acrophases were not evaluated because when no significant cosinor fit is found (as in Figure 1B,
C, E, F, G, I, K, L), the acrophase is not a valid parameter to
compare groups.

sAPPa and sAPPb mesors unchanged while Ab40 mesor
decreases with age, and Ab42 mesor decreases with age
and amyloidosis
In YNC, sAPPa levels had a mean mesor over 36 hours of
731.0 ng/mL (min.: 250.4 ng/mL, max.: 1254 ng/mL). In
Amyloid2, sAPPa levels displayed a mean mesor of 1100 ng/
mL (min.: 191.5 ng/mL, max.: 2805 ng/mL). The Amyloid+
group had a mean sAPPa mesor level of 898.1 ng/mL (min.:
386 ng/mL, max.: 1353 ng/mL). None of these groups’ sAPPa
mesors were significantly different from one another (YNC vs.
Amyloid2: p = 0.2; YNC vs. Amyloid+: p = 0.08; Amyloid2 vs.
Amyloid+: p = 0.3) (Table 1).
The mean sAPPb mesor in the YNC group was 416.5 ng/mL
(min.: 229 ng/mL, max.: 928.3 ng/mL). This was not significantly
different (p = 0.6) from the mean sAPPb mesor in Amyloid2
(383.2 ng/mL; min.: 100.5 ng/mL, max.: 831.9 ng/mL), nor
from the mean sAPPb mesor level in Amyloid+ (344.3 ng/mL;
min.: 117.5 ng/mL, max.: 899.8 ng/mL; p = 0.4). The mean
sAPPb mesors in the Amyloid2 and Amyloid+ groups were also
not significantly different from one another (p = 0.6) (Table 2).
The YNC group had a mean Ab40 mesor of 8966 pg/mL (min.:
2430 pg/mL, max.: 13433 pg/mL). The Amyloid2 group had a
29% lower mean Ab40 mesor (6373 pg/mL; min.: 1332 pg/mL,
max.: 11089 pg/mL) than the YNC group (*p = 0.04). The
Amyloid+ group exhibited a 35% lower Ab40 mesor (5872 pg/
mL; min.: 1505 pg/mL, max.: 10768 pg/mL) than the YNC
group (*p = 0.02). There was no statistically significant difference
in mean Ab40 mesor values between the Amyloid2 and Amyloid+
groups (p = 0.7) (Table 3).
The mean Ab42 mesors were significantly different among all
groups. On average, the YNC group’s Ab42 mesor was 830.7 pg/
mL (min.: 255.7 pg/mL, max.: 1683 pg/mL). The Amyloid2
group had a 38% lower mean Ab42 mesor (518.6 pg/mL; min.:
195 pg/mL, max.: 885.3 pg/mL) than the YNC group (*p = 0.02).
The Amyloid+ group had a 75% lower mean Ab42 mesor
(206.9 pg/mL; min.: 48.85 pg/mL, max.: 471.3 pg/mL) than the

No diurnal pattern exhibited in total protein levels of
Amyloid2 and Amyloid+ groups
As a negative control for diurnal rhythms, we assayed total CSF
protein over 36 hours using a micro BCA assay. Total protein data
was only available for a subset of participants in each group. We
measured that, on average, total protein concentrations were
significantly lower in YNC as compared with the older participants
(YNC = 797.2 mg/mL (n = 6), Amyloid2 = 895.1 mg/mL (n = 6),
and Amyloid+ = 871.4 mg/mL (n = 5), ***p,0.0001). A cosinor fit
was applied to the mean of each group’s total protein level. A
significant cosinor fit was found in the YNC group, with an
amplitude 4.5% (95% CI: 26.1% to 22.9%). Cosinor fits for both
older groups were insignificant because the amplitudes’ 95% CIs
crossed zero: Amyloid2 (95% CI: 21.4% to +8.6%) and
Amyloid+ (95% CI: 28.4% to +1.4%) (Figure S3). Acrophase
was calculated only for the YNC (1.160.7 h), as the other groups
did not exhibit a significant cosinor fit. Owing to high inter-subject
variability within the YNC group and approximately only 46% of
participants having BCA data for analysis, we cannot conclude
that a significant cosinor fit in the YNC group would hold up with
a full dataset.

sAPP and Ab positively correlated, except in amyloidosis
In order to determine the relationship of a- and b-secretases on
APP processing, correlations of sAPPa, sAPPb, Ab40, and Ab42
were calculated in CSF from a single time-point at the onset of the
study (between 7:30 A.M. and 9:00 A.M.) in the three participant
groups: YNC, Amyloid2, and Amyloid+. Soluble APPa and
sAPPb were positively correlated in all groups (YNC: r = 0.95,

Table 1. Comparison of Cosinor Parameters for sAPPa among 3 groups.

Participant Group

Amplitude, ng/mL Mean (SD)

Mesor, ng/mL Mean
(SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

Acrophase (h) Mean (SD)

YNC (n = 13)

75.74 (11.15)

731.0 (86.65)

10.93 (1.5)

3.9 (5.6)

Amyloid2 (n = 19)

59.24 (8.317)

1100 (159.4)

6.7 (0.87)

2.7 (5.3)

Amyloid+ (n = 17)

51.1 (9.734)

898.1 (72.95)

6.04 (1.14)

3.9 (6.2)

Abbreviations: YNC: participants classified as young (cognitively) normal healthy controls; Amyloid2: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration greater than 350 pg/mL; Amyloid+: participants with MCBP greater than or equal
to 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration less than 350 pg/mL.
doi:10.1371/journal.pone.0089998.t001
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Table 2. Comparison of Cosinor Parameters for sAPPb among 3 groups.

Participant Group

Amplitude, ng/mL Mean (SD)

Mesor, ng/mL Mean
(SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

Acrophase (h) Mean (SD)

YNC (n = 13)

54.61 (5.9)

416.5 (50.39)

14.38 (1.58)

1.5 (2.0)

Amyloid2 (n = 19)

32.78 (7.66)

383.2 (47.76)

8.15 (1.21)

1.5 (2.4)

Amyloid+ (n = 17)

31.57 (6.95)

344.3 (55.27)

9.16 (1.42)

3.5 (6.2)

Abbreviations: YNC: participants classified as young (cognitively) normal healthy controls; Amyloid2: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration greater than 350 pg/mL; Amyloid+: participants with MCBP greater than or equal
to 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration less than 350 pg/mL.
doi:10.1371/journal.pone.0089998.t002

hour 0), for each participant sAPPb and sAPPa concentrations
were individually averaged over 36 hours. Each participant’s
36 hour averaged sAPPb concentration and their respective
36 hour averaged sAPPa concentration were then used to
determine the mean sAPPb/sAPPa ratio. These mean ratios were
then, in turn, averaged to determine a participant group average
of the mean sAPPb/sAPPa ratio. The mean sAPPb to sAPPa ratio
was 0.5960.04 (n = 15) in YNC, which was significantly higher
(*p = 0.03) than either the Amyloid2 (n = 19) or the Amyloid+
(n = 17) ratio (both ratios were 0.4260.06) (Figure S4A).
Additionally, each participant’s sAPPb mesor and sAPPa mesor
were used to determine individual mesor sAPPb/sAPPa ratios.
The mesor sAPPb to sAPPa ratio was 0.5960.04 (n = 15) in YNC,
which was significantly higher than the Amyloid2 and Amyloid+
mesor ratios. Mesor ratio means and error for the two older groups
were identical to averaged ratios and errors (Figure S4B).
The results from the mean sAPPb to sAPPa ratio and the mesor
sAPPb to sAPPa ratio are almost identical because they represent
nearly the same parameter. These results also contrast with the
increased sAPPb to sAPPa ratio with amyloidosis when only the
first CSF sample collected (hour 0) is analyzed. The mean
concentrations and the mesor are calculated from runs on multiple
ELISA plates over many months and may not be directly
comparable, while the hour 0 samples were run on the same
plate and can be directly compared. Thus, we conclude the
increased sAPPb to sAPPa ratio in amyloidosis when measuring at
hour 0 is most reliable as it avoids assay drift and also the modeling
of the calculated mesor value.

***p,0.0001; Amyloid2: r = 0.93, ***p,0.0001; Amyloid+:
r = 0.86, **p = 0.002) (Figure 3A). Soluble APPb was positively
correlated to Ab40 in YNC (r = 0.84, *p = 0.02), and Amyloid2
groups (r = 0.68, **p = 0.005), but not in the Amyloid+ group
(r = 0.25, p = 0.5) (Figure 3B). Soluble APPa was also positively
correlated to Ab40 in the Amyloid2 group (r = 0.84, **p = 0.003),
and trended toward a positive correlation in the YNC group
(r = 0.69, p = 0.1). There was not any strong correlation between
sAPPa and Ab40 in the Amyloid+ group (r = 0.2, p = 0.6)
(Figure 3D). There was a trend for sAPPb to be positively
correlated to Ab42 in YNC (r = 0.57, p = 0.2), and Amyloid2
groups (r = 0.5, p = 0.1); but there was no correlation in the
Amyloid+ group (r = 20.08, p = 0.8) (Figure 3C). Similarly, sAPPa
also trended to a positive correlation with Ab42 in YNC (r = 0.39,
p = 0.4) and Amyloid2 groups (r = 0.64, p = 0.04); but not in the
Amyloid+ group (r = 20.01, p = 1.0) (Figure 3E).

sAPPb/sAPPa ratio is elevated in amyloidosis
In order to determine the effects of age and amyloidosis on the
APP processing pathways, APP metabolites from a single CSF
time-point at the onset of the study (between 8:00 A.M. and 10:00
A.M.) were compared among three participant groups: YNC,
Amyloid2, and Amyloid+. The sAPPb to sAPPa ratio was
0.2660.01 (<1:3 ratio, n = 15) in YNC, and 0.2660.02 (<1:3
ratio, n = 15) in Amyloid2. However, the ratio increased to
0.3260.05 (<1:2 ratio, n = 10) for Amyloid+. The sAPPb/sAPPa
ratio was significantly higher in Amyloid+ participants than in
Amyloid2 (*p = 0.02) and YNC (**p = 0.002) (Figure 4A). However, taken independently, mean sAPPa and sAPPb concentrations were not significantly different among groups, suggesting that
the sAPPb/sAPPa ratio corrected for other variances which were
not associated with amyloidosis (Figure 4B–C).
In order to determine if there was a similar pattern in sAPPb/
sAPPa ratio differences among groups when measurements were
taken over a full 36 hour time-course (versus at a single time-point:

Discussion
We evaluated whether APP exhibited diurnal fluctuations
similar to that of Ab, which would help inform why Ab
demonstrates a diurnal pattern. We also determined normal aand b-processing of APP in the human CNS and assessed whether
AD pathology is associated with alterations in APP processing.

Table 3. Comparison of Cosinor Parameters for Ab40 among 3 groups.

Participant Group

Amplitude, pg/mL Mean (SD)

Mesor, pg/mL Mean
(SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

Acrophase (h) Mean (SD)

YNC (n = 13)

698.8 (143.8)

8966 (936.1)

8.46 (1.52)

6.7 (7.1)

Amyloid2 (n = 15)

526.3 (80.29)

6373 (762)

9.13 (1.18)

7.1 (6.9)

Amyloid+ (n = 14)

505.5 (97.67)

5872 (795.8)

9.09 (1.5)

8.2 (8.1)

Abbreviations: YNC: participants classified as young (cognitively) normal healthy controls; Amyloid2: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration greater than 350 pg/mL; Amyloid+: participants with MCBP greater than or equal
to 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration less than 350 pg/mL.
doi:10.1371/journal.pone.0089998.t003

PLOS ONE | www.plosone.org

8

March 2014 | Volume 9 | Issue 3 | e89998

Human Amyloid Precursor Protein Diurnal Patterns

Table 4. Comparison of Cosinor Parameters for Ab42 among 3 groups.

Participant Group

Amplitude, pg/mL Mean (SD)

Mesor, pg/mL Mean
(SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

Acrophase (h) Mean (SD)

YNC (n = 13)

64.26 (10.06)

830.7 (117.6)

9.43 (1.59)

2.9 (2.7)

Amyloid2 (n = 15)

39.49 (5.9)

518.6 (54.08)

8.04 (1.2)

1.7 (1.8)

Amyloid+ (n = 14)

14.5 (2.73)

206.9 (26.74)

7.99 (1.65)

5.0 (6.2)

Abbreviations: YNC: participants classified as young (cognitively) normal healthy controls; Amyloid2: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration greater than 350 pg/mL; Amyloid+: participants with MCBP greater than or equal
to 0.18, or, in the absence of MCBP measurements, a mean CSF Ab42 concentration less than 350 pg/mL.
doi:10.1371/journal.pone.0089998.t004

The regulation of APP by a- and b-secretase over time,
including potential dynamic changes of sAPPa and sAPPb within
an individual, has not been previously evaluated, although Ab
diurnal activity has been described in healthy, young human
participants [7]. We recently demonstrated that both in CSF [9]
and in plasma [10], the physiological Ab diurnal fluctuation
described in young participants diminishes significantly with
increasing age, but is not further decreased in amyloidosis.
Further, previous studies in mice indicated that sleep regulation
may play a critical role in the risk and development of AD [8], but
more recent findings indicate that it may be Ab aggregation that
disrupts both the sleep-wake cycle and Ab diurnal fluctuation [21].
For example, longitudinal studies have found a strong relationship
between sleep circadian patterns, as well as sleep disordered
breathing and risk of mild cognitive impairment and AD [22–23].
Therefore, we sought to determine the relationship between aand b- processing pathways in individuals over time, and also
determine if APP regulation contributes to Ab circadian patterns.
In the YNC group, we found that sAPPa, sAPPb, Ab40, and
Ab42 concentrations were dynamic over 36 hours, with diurnal
patterns. The lowest concentrations were in the morning
(approximately 9:00 A.M.), and the concentrations peaked in the
evening, approximately12 hours later. This suggests that in the
YNC group, dynamic changes in these protein levels were due to
dynamic changes in APP availability, whether by its production
(transcription or translation) or transport to the site of processing
(i.e. axonal transport). Amyloid-b also demonstrated a diurnal
pattern with a peak and trough approximately three hours after
sAPPa and sAPPb. This suggests that APP diurnal availability
likely plays a role in Ab diurnal patterns.
Diurnal patterns of sAPPa and sAPPb were diminished in the
Amyloid2 group. Ab42 did not show any significant diurnal
pattern in the Amyloid2 group similarly to prior work from our
laboratory [9]. However, whereas our present work did not show a
diurnal pattern of Ab40 in the Amyloid2 group, there was a slight,
but significant diurnal pattern observed in [9]. Potential reasons
for this discrepancy include different ELISA assays employed for
the different studies. Both Ab ELISA assays from [9] used 3D6 as
detection antibodies, and capture antibodies were 2G3 (anti-Ab40)
and 21F12 (anti-Ab42). These are fairly common Ab antibodies,
and those assays provided lower intra-sample CV of duplicates
than the antibodies we used for Ab in this study. More noisy data
may have contributed to slightly differing results. Further,
although several of our participants in the two studies overlapped,
many participants were not from the same dataset as [9]. Lastly,
[9] had more variable sample size among groups (YNC = 20,
Amyloid2 = 15. Amyloid+ = 11), whereas our groups were more
balanced (YNC = 13; Amyloid2 = 15; Amyloid+ = 14). Taken
together, these findings indicate that with age there is a loss of
APP dynamics or availability, which results in the noted loss of not
PLOS ONE | www.plosone.org

only sAPP, but also Ab diurnal patterns. It was recently reported
that sleep facilitates Ab clearance [24], thus the physiological
tightly-regulated diurnal patterns of Ab may diminish with age due
to an increase in sleep fragmentation that is common in normal
aging [25] or by a general increased Ab production due to
wakefulness [8].
Lack of a diurnal pattern of sAPPa and sAPPb was exhibited to
a similar extent in the Amyloid+ group as was seen in the
Amyloid2 group. However, the diurnal patterns in Ab40 and Ab42
were even more significantly diminished in the Amyloid+ group
than was seen in the Amyloid2 group. The further marked
decrease in Ab40 and Ab42 diurnal patterns in the presence of
amyloidosis does not correspond to any decrease in sAPP diurnal
patterns. This disconnect may be an effect of downstream APP
cleavage events and not due to APP dynamics or availability,
which seems to be the case in general aging. Potentially the extent
of c-secretase cleavage of APP, which is controlled by availability
of the c-secretase components or the c-secretase level of activity,
may play a role in diminishing the diurnal patterns of the two Ab
species we measured. Also, the build-up of Ab plaques in the
brains of those with amyloidosis may serve as a buffering system
that decreases the dynamic nature of Ab that is observed in
healthy, younger humans. Although, the Amyloid+ group has a
lower Ab42 amplitude than YNC or Amyloid2, this result is not
intended to suggest that Ab42 amplitude should be added as an
Alzheimer’s diagnostic test. Currently, other tests (a combination
of CSF Ab42/tau, PIB PET, and FDG PET scanning) have good
predictive outcomes for determining AD diagnosis. The potential
minor additive diagnostic benefit of Ab42 amplitude is questionable and would require a patient to be catheterized for 24 hours.
Further, sAPPa and sAPPb were positively correlated in all
groups. Positive correlation of the a- and b-secretase products
suggests a non-competitive model of APP pathways: that the total
APP availability drove changes in sAPPa and sAPPb. Soluble
APPa and sAPPb were positively correlated with both Ab species
in YNC and elderly controls. However, the correlation between
the sAPP species and Ab42 was lost with amyloidosis. Prior
evidence in the human CNS shows a positive sAPPa to sAPPb
correlation in individuals also suggesting non-competitive a- and
b-pathways [26–29] However, in vitro studies of secretase inhibitors
or activators, or genetically decreasing BACE1 (a b-secretase
protein) or ADAM10 (an a-secretase protein) [30–36] support the
hypothesis that a- and b-secretase pathways compete for the same
APP pool due to inverse correlations during secretase inhibition
(i.e. when processing through one pathway decreases, the
processing of the alternative pathway increases). These studies
suggest that there may be an inverse relationship between the aand b- pathways in inhibitor studies, while our study shows that
during physiologic APP processing in the human CNS, a- and bprocessing are positively correlated.
9
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Figure 3. Correlations between APP metabolites. Amyloid Precursor Protein metabolites in the first CSF collection for each participant were
correlated to determine relationships between the APP processing pathways. Each participant’s cerebrospinal fluid sample was drawn between 7:30
A.M. and 9:00 A.M. The four APP metabolites’ concentrations were measured using four separate metabolite-specific ELISAs, and, for each participant,
plotted against one another. The correlation coefficient was then calculated for each group. A) sAPPa and sAPPb concentrations for each participant
were plotted against one another and showed a positive correlation in all groups (YNC: r = 0.95, ***p,0.0001; Amyloid2: r = 0.93, ***p,0.0001;
Amyloid+: r = 0.86, **p = 0.0015). B) sAPPb and Ab40 concentrations for each participant were plotted against one another : YNC: r = 0.84, *p = 0.018;
Amyloid2: r = 0.68, **p = 0.0048; Amyloid+: r = 0.25, p = 0.52). C) sAPPb and Ab42 concentrations for each participant were plotted against one
another and a positive correlation was detected in YNC (r = 0.57, p = 0.18) and Amyloid2 groups (r = 0.5, p = 0.14), but no correlation was detected in
the Amyloid+ group (r = 20.08, p = 0.84). D) sAPPa and Ab40 concentrations for each participant were plotted against one another and compared
among the groups: YNC: r = 0.69, p = 0.09; Amyloid2: r = 0.84, **p = 0.0025; Amyloid+: r = 0.2, p = 0.6). E) sAPPa and Ab42 concentrations for each
participant were plotted against one another. The correlation results are as follows: YNC (r = 0.39, p = 0.38); Amyloid2 (r = 0.64, p = 0.04); and
Amyloid+ (r = 20.01, p = 0.97).
doi:10.1371/journal.pone.0089998.g003

higher in Amyloid+ participants than in Amyloid2 participants
and YNC; therefore, the ratio may be a useful indicator of Ab
plaque deposition. This result further supports the hypothesis that
sporadic AD may be the result of an upregulation of b-secretase
processing of APP, with respect to a-secretase. Our results are
consistent with recent findings of increased CSF sAPPb in the
presence of decreased Ab42 and increased tau [26–27]. However,
some reports indicate increased sAPPa [28] while others show no
difference [26–27], similarly to our findings. Recently, it was

We found that the molar ratio of sAPPa to sAPPb was
approximately 3:1 with a shift to 2:1 from a- to b-processing in the
setting of amyloid deposition. The differences in ratios among
these groups were not age-related since there was no significant
difference between YNC and Amyloid2 groups. Prior reports
estimated a to b ratios of 10:1 [31,33], however, these in vitro
estimates likely had lower b-secretase activity than is present in the
CNS, since b-secretase is mostly found in the brain [12–14]. We
further showed that on average sAPPb/sAPPa was significantly
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Figure 4. Separating participant groups by the sAPPb/sAPPa ratio. We compared sAPPb and sAPPa concentrations, as well as the sAPPb/
sAPPa ratio, among groups using the first CSF collection. Each participant’s first CSF sample was drawn between 7:30 A.M. and 9:00A.M. sAPPb and
sAPPa concentrations were measured using two separate metabolite-specific ELISAs. Student’s t-tests were used and graphs show 95% Confidence
Interval error bars. A) sAPPb/sAPPa ratio was higher with amyloid deposition (Amyloid+) as compared to healthy, older controls (Amyloid2)
(*p = 0.02) or young healthy controls (YNC) (**p = 0.002). No significant difference was detected between the ratio of the YNC and Amyloid2 groups
(p = 0.6). B) sAPPa concentrations were not significantly higher in Amyloid+ than in YNC (p = 1.0) or Amyloid2 (p = 0.5). No significant difference was
detected between the sAPPa concentration of the YNC and Amyloid2 groups (p = 0.4). C) sAPPb concentrations were not significantly higher in
Amyloid+ than in YNC (p = 0.09) nor Amyloid2 (p = 0.6). No significant difference was detected between sAPPb concentrations from the YNC and
Amyloid2 groups (p = 0.3).
doi:10.1371/journal.pone.0089998.g004

reported that neither sAPPa, nor sAPPb, measured from CSF by
both ELISA and mass spectrometry, was altered in AD [32]. This
parallels results of an ELISA study from a decade earlier that also
showed no difference in sAPPa, nor in sAPPb, when healthy
controls were compared to sporadic AD patients [37]. None of
these groups, however, reported sAPP metabolite ratios. To
summarize, amyloidosis, and not age, was associated with a
constitutive change in a- to b- processing of APP among
individuals.
In conclusion, in our study we report diurnal dynamics of APP
metabolites diminished with age, and, only for Ab, were further
attenuated with amyloidosis. These results may explain some
possible confounding factors of other studies that have measured
sAPPa, sAPPb, Ab40, and Ab42 levels in CSF collected at a single
time point from AD versus non-AD participants. This may clarify
the discrepancy in results and the wide range of concentrations of
APP metabolites presented by various groups. We also indicate
that taking a ratio of sAPPb/sAPPa may correct for these
inconsistencies. Further, we demonstrated that there is a positive
correlation among soluble APP metabolites, which diminishes with
amyloidosis. This dissociation is probably due to CSF Ab42 levels
in AD no longer being representative of APP processing due to the
sequestering of Ab, particularly Ab42, in plaques.
Advantages of this study included that the samples were
obtained from the human CNS in three different participant
groups and total protein concentrations showed stability over time
in the older groups. Fewer than half of the YNC had total protein
data available, and this, along with high inter-subject variability,
does not allow us to state conclusively whether a diurnal pattern of
total protein does or does not exist in the whole YNC group.
However, the similar diurnal patterns among APP metabolites
seem to indicate that CSF APP dynamics are likely independent of
CSF total protein levels. Nevertheless, we did not directly measure
a- and b-secretase activities or production rates of APP
metabolites. Thus, our study does not answer the question of
what causes APP to rise and fall in a diurnal pattern, although
possibilities include transcription, translation, or transport. Future
studies into APP processing pathways, including production rates
of APP and a- and b-secretases may be useful to inform about
causes of APP dynamics.
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Supporting Information
Figure S1 Specificity and selectivity of the sAPPa ELISA.
Titration curves of sAPPa and sAPPb standards were run on the
sAPPa ELISA assay. The OD values from the CSF samples fell
well above baseline, and within the linear range of the sAPPa
standard curve. This demonstrates that this assay is sensitive
enough to measure sAPPa from the biological samples in this
study. The sAPPb standard curve’s OD values were zero, even at
the highest concentration of 300 ng/mL, which indicates that
sAPPb does not cross-react with the sAPPa assay.
(TIFF)
Figure S2 Specificity and selectivity of the sAPPb ELISA.

Titration curves of sAPPa and sAPPb standards were run on the
sAPPb ELISA assay. The OD values from the CSF samples fell
well above baseline, and within the linear range of the sAPPb
standard curve. This demonstrates that this assay is sensitive
enough to measure sAPPb from the biological samples in this
study. The optical density (OD) for the sAPPb standard of 8.5 ng/
mL was approximately the same as the OD value for the sAPPa
standard at a concentration of 300 ng/mL. This indicates that this
ELISA is approximately 35-fold more selective for sAPPb than for
sAPPa. Thus, any cross-reactivity is negligible.
(TIFF)
Figure S3 No diurnal pattern in total CSF protein
concentrations of Amyloid2 and Amyloid+ groups.
Participants’ total protein concentrations in CSF over 36 hours
were determined by using a micro BCA assay. For each
participant group, the mean total protein concentration for each
hour was calculated and plotted. Cosinor fits were applied to each
group’s hourly mean total protein concentration. A significant
cosinor fit was found in the YNC group (n = 6), with an amplitude
4.5% (95% CI: 26.1% to 22.9%). No significant diurnal patterns
were apparent in the Amyloid2 group (n = 6; 95% CI: 21.4% to
+8.6%) and the Amyloid+ group (n = 5; 95% CI: 28.4% to
+1.4%).
(TIFF)
Figure S4 sAPPb/sAPPa ratios determined from
36 hour time-course. We measured the sAPPb/sAPPa ratio
for each individual based on that participant’s sAPPb and sAPPa
concentrations over the 36 hour time-course. Individual ratios
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were calculated and averaged within participant groups. Student’s
t-test was used and graphs show 95% Confidence Interval error
bars. A) Mean sAPPb/sAPPa ratio was calculated for each
participant using that participant’s 36 hour mean sAPPb concentration and 36 hour mean sAPPa concentration. Individual ratios
were averaged in their respective participant groups. The groupaveraged mean sAPPb/sAPPa ratio is significantly higher in YNC
than in Amyloid2 (*p = 0.03) or in Amyloid+ (*p = 0.03). No
significant difference was detected between the group-averaged
mean sAPPb/sAPPa ratio of the Amyloid2 and Amyloid+ groups
(p = 0.92). B) Mesor sAPPb/sAPPa ratio was calculated for each
participant using the sAPPb mesor value (determined from the
cosinor fit of that participant’s 36 hour sAPPb concentrations) and
the sAPPa mesor value (determined from the cosinor fit of the
36 hour sAPPa concentrations). The mesor sAPPb/sAPPa ratio is
significantly higher in YNC than in Amyloid2 (*p = 0.03) or in
Amyloid+ (*p = 0.03). No significant difference was detected

between the mesor sAPPb/sAPPa ratio of the Amyloid2 and
Amyloid+ groups (p = 0.93).
(TIFF)
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